Amazon Pharmacy tests low-volume mail-order sector: Analysts

In This Article:

Amazon’s new pharmacy service, while not surprising, increases pressure on brick-and-mortar pharmacies which have already been impacted by the global pandemic this year.

Amazon (AMZN) Pharmacy is the latest move from the e-retail giant after it acquired mail-order startup Pill Pack for $750 million in 2018. The service, offered in 45 states, includes discounted drug prices as well as payment through insurance, cash and health savings accounts— the latter of which has already been possible on the site. Prime members will get free two-day shipping, while non-Prime members can pay $5.99 for the same. The service also allows discounts to be applied to traditional pharmacies.

Key components of the strategy rely on the Prime member network and Cigna’s (CI) spinoff Evernorth, and ExpressScripts, for the discount program— which can also be used at traditional retail pharmacies.

Like GoodRx (GDRX), Amazon is offering discounted prices if patients choose to pay without insurance — which offers both the opportunity to price compare as well as open the door to convenient prescription ordering for the uninsured— a typically low-volume market — and possibly push Amazon, eventually, into direct negotiations with drug companies.

“If they are negotiating rates on drugs ... it sort of becomes a PBM [pharmacy benefits manager] for uninsured people,” said Craig Garthwaite, professor of strategy and director of the Program on Healthcare at Northwestern University’s Kellogg School.

Garthwaite told Yahoo Finance that the announcement is less of a disruption and more of an additional competitor in the space.

Close-up of logo for Pill Pack by Amazon Pharmacy on white paper, San Ramon, California, December 15, 2019. (Photo by Smith Collection/Gado/Getty Images)
Close-up of logo for Pill Pack by Amazon Pharmacy on white paper, San Ramon, California, December 15, 2019. (Photo by Smith Collection/Gado/Getty Images)

Amazon’s delivery network is already so robust that it can outdo other pharmacies since the “cost of delivering and marginal cost of startup is less than its competitors,” he said.

JPMorgan analysts said Tuesday that the news is hardly a surprise and is unlikely to be a true disruption for multiple reasons, including its target customer base.

“We don’t believe Amazon has a specialty solution at this point, which combines fulfillment with clinical capabilities (note that specialty currently represents roughly half of total prescription drug spend),” analysts noted, adding that the cash pay market is just under 5% of the overall prescription market.

What remains to be seen is whether or not it boosts Prime membership, and if it can capitalize on mail-order, which has traditionally had low pickup.

“Each of the large PBMs has offered mail pharmacy services for over 30 years. Interestingly, despite convenience, mail utilization has actually been steadily declining per data from IQVIA data ... mail accounted for just 5% of total adjusted scripts in 2019, down from double-digit levels a decade ago,” according to JPM.